Based on this assumption, GFAP and CHI3L1 as markers of astrocytic and microglial activation showed higher levels in the CSF and serum of PMS patients compared to RRMS patients (11, 12, 18, 27, 29, 36–38). Here, CHI3L1 is linked to relapsing-remitting multiple sclerosis.